← Back to patent-cliff list
Omaveloxolone
Tier C — Watch / tradeOmaveloxolone
-
Originator
2023
First approval
-
Expiry (public)
$0.52B ▲
Peak sales
Small molecule
Type
Targets：Nrf2
Brand：SKYCLARYS
Indications (approved)：Friedreich's ataxia
Regional status
US
Approved
2023-02-28
EU
Approved
2024-02-09
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Omaveloxolone?
Approved indications include: Friedreich's ataxia.
When does the Omaveloxolone patent expire?
No public expiry year is available for Omaveloxolone yet; this page updates once verified.
How do I get a quote for Omaveloxolone intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27